| Name | 6-[4-(1-cyclohexyltetrazol-5-yl)butoxy]-1H-quinolin-2-one |
|---|---|
| Synonyms |
3,4-dehydro-cilostazol
UNII-5M77W4SPE0 QUI006 |
| Description | 3,4-Dehydro Cilostazol (OPC-13015) is an active metabolite of Cilostazol (CLZ; HY-17464). 3,4-Dehydro Cilostazol is used for pharmacokinetic study[1]. |
|---|---|
| Related Catalog | |
| In Vivo | 3,4-Dehydro Cilostazol (OPC-13015; Oral; 1 mg/kg GLZ and 10 mg/kg CLZ) has a T1/2 of 3.94 hours, a Cmax of 1.39 μM and an AUC0-24 of 4.69 μg•h/ml. The plasma concentration time profiles of GLZ, CLZ & its active metabolite DCLZ are traceable up to 24 h, 12 h and 12 h respectively by oral administration at 1 mg/kg dose of GLZ and 10 mg/kg CLZ[1]. Animal Model: Male Wistar rats weighing 200 g[1] Dosage: 1 mg/kg Glipizide (GLZ) and 10 mg/kg Cilostazol (CLZ) (Pharmacokinetic Analysis) Administration: Oral Result: Had a T1/2 of 3.94 hours, a Cmax of 1.39 μM and an AUC0-24 of 4.69 μg•h/ml. |
| References |
| Density | 1.342g/cm3 |
|---|---|
| Boiling Point | 675.937ºC at 760 mmHg |
| Melting Point | 179-180ºC |
| Molecular Formula | C20H25N5O2 |
| Molecular Weight | 367.44500 |
| Flash Point | 362.594ºC |
| Exact Mass | 367.20100 |
| PSA | 85.69000 |
| LogP | 3.42150 |
| Index of Refraction | 1.676 |
| Symbol |
GHS07 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H302 |
| Precautionary Statements | P301 + P312 + P330 |
| RIDADR | NONH for all modes of transport |
|
~0%
Detail
|
| Literature: WO2006/22488 A1, ; Page/Page column 3 ; |
|
~85%
73963-62-9 |
| Literature: Heterocycles, , vol. 78, # 1 p. 189 - 195 |
| Precursor 3 | |
|---|---|
| DownStream 0 | |